379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study

• DOI: 10.1016/j.annonc.2023.09.556
• Publication Date: 2023-10-20T11:33:36Z
• Authors: P. Schmid; P.J. Wysocki; C.X. Ma; Y.H. Park; R. Fernandes; S. Lord; R.D. Baird; C. Prady; K.H. Jung; J. Asselah; R. Huisden; R. Stewart; K. Heider; P. Vukovic; N. Denduluri; Z. Nowecki